Comprehensive Income (Loss), Net of Tax, Attributable to Parent of Vaxxinity, Inc. from 30 Sep 2022 to 31 Dec 2023

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Vaxxinity, Inc. annual and quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 30 Sep 2022 to 31 Dec 2023.
  • Vaxxinity, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Sep 2023 was $13,134,000, a 33% increase year-over-year.
  • Vaxxinity, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $56,729,000, a 25% increase from 2022.
Source SEC data
View on sec.gov
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)

Vaxxinity, Inc. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $56,729,000 +$18,690,000 +25% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2024 2023 FY
2022 $75,419,000 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY

Vaxxinity, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2023 $13,134,000 +$6,333,000 +33% 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2023 2023 Q3
Q3 2022 $19,467,000 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.